Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Predictive Model for Major Adverse Aortic Events in Patients with Abdominal Aortic Aneurysm Using Clinical and Biomarker Data.

International journal of molecular sciences·2026
Same author

A Prospective Head-to-Head Comparison of HER2-Targeted and 18F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

Clinical nuclear medicine·2026
Same author

Dual-Metal MOF-Derived Carbon Fibers Achieve Efficient Polysulfide Anchoring and Conversion Simultaneously in Li-S Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Trefoil Factor 3 as a Biomarker for Peripheral Artery Disease.

Biomolecules·2026
Same author

The Association Between Abnormal Electrocardiogram Findings and the Ankle Brachial Index.

Medicina (Kaunas, Lithuania)·2026
Same author

Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy.

Cancer medicine·2026

Related Experiment Video

Updated: Jan 7, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.6K

Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor

Tianyu Zeng1, Ben Li2, Jialin Xu1

  • 1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.

Analytical Chemistry
|December 12, 2025
PubMed
Summary

This study introduces a novel biomimetic platform for capturing and identifying rare circulating tumor cells (CTCs). The technology enables visual detection of Trop-2 expression, aiding in cancer diagnosis and treatment monitoring.

More Related Videos

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

458
Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.9K

Related Experiment Videos

Last Updated: Jan 7, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.6K
Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

458
Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.9K

Area of Science:

  • Biomaterials Science
  • Oncology
  • Nanotechnology

Background:

  • Circulating tumor cells (CTCs) are crucial biomarkers in oncology, but their rarity and heterogeneity pose detection challenges.
  • Current methods for CTC capture and identification require sophisticated instrumentation and can impact cell viability.

Purpose of the Study:

  • To develop an innovative, instrument-free platform for the non-destructive capture and direct identification of CTCs.
  • To enable visual assessment of specific biomarkers, such as Trop-2, on captured CTCs for personalized therapy.

Main Methods:

  • Engineered a biomimetic platform integrating platelet membrane-camouflaged magnetic beads (PM-MBs) with aptamer-based polyvalent antibody mimics (PAMs) (PM-PAM platform).
  • Utilized rolling circle amplification (RCA) for PAM synthesis and metal-organic framework (MOF) nanozymes for colorimetric signal generation.
  • Demonstrated platform performance using triple-negative breast cancer (TNBC) patient samples undergoing sacituzumab govitecan (SG) therapy.

Main Results:

  • Achieved exceptional CTC capture efficiency exceeding 90%.
  • Enabled instrument-free, visual detection of Trop-2 expression on captured CTCs.
  • Preserved cell viability and demonstrated 100% diagnostic specificity.

Conclusions:

  • The PM-PAM platform offers a cost-effective, adaptable solution for liquid biopsy, establishing a new paradigm for CTC analysis.
  • This technology shows promise for monitoring antibody-drug conjugate (ADC) treatment efficacy through dynamic Trop-2 expression analysis in breast cancer.